Independent directory Public ClinicalTrials.gov records United States
Clinical Trials Finder
Objective public record navigation
Search Results

Search by objective public record fields.

Search by query text, NCT ID, condition, intervention, sponsor, city, state, recruitment status, phase, study type, healthy volunteer eligibility, sex, or age. Results are retrieved from ClinicalTrials.gov and synchronized into the directory. Search pages remain noindex by default.

Clear filters
ClinicalTrials.gov public records Last synced Sep 10, 2026, 4:40 PM EDT

Data is sourced from official ClinicalTrials.gov public API records. Always review the official ClinicalTrials.gov record for the latest information.

Showing 1–24 of 113 matching trials from the live ClinicalTrials.gov search.
Local D1 index available.
Filters: Condition: Coronavirus 19 Clear all
Not listed No phase listed Observational Accepts healthy volunteers

Restoring Non-Emergent Cardiovascular Care in the Peri- COVID-19 Era

NCT04636021
View directory record Official record
Conditions
Corona Virus Infection
Interventions
COVID-19 testing
Diagnostic Test
Lead sponsor
Pinnacle Health Cardiovascular Institute
Network
Eligibility
Not listed
Enrollment
1,000 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2020 – 2022
U.S. locations
1
States / cities
Harrisburg, Pennsylvania
Source: ClinicalTrials.gov public record
Updated Nov 18, 2020 · Synced Sep 10, 2026, 4:40 PM EDT
Completed Early Phase 1 Interventional

CoVID-19 Plasma in Treatment of COVID-19 Patients

NCT04355897
View directory record Official record
Conditions
COVID 19
Interventions
Convalescent COVID 19 Plasma
Biological
Lead sponsor
The Christ Hospital
Other
Eligibility
18 Years to 80 Years
Enrollment
22 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2020
U.S. locations
2
States / cities
Cincinnati, Ohio • Cleveland, Ohio
Source: ClinicalTrials.gov public record
Updated Jan 4, 2024 · Synced Sep 10, 2026, 4:40 PM EDT
Terminated Phase 2 Interventional

Pemziviptadil (PB1046), a Long-acting, Sustained Release Human VIP Analogue, Intended to Provide Clinical Improvement to Hospitalized COVID-19 Patients at High Risk for Rapid Clinical Deterioration and Acute Respiratory Distress Syndrome (ARDS).

NCT04433546
View directory record Official record
Conditions
Acute Respiratory Distress Syndrome, Coronavirus, Hypoxic Respiratory Failure, Hypoxemic Respiratory Failure, Respiratory Complication, Respiratory Insufficiency, Cardiac Dysfunction, Pneumonia, Pulmonary Edema, Pulmonary Inflammation, Respiratory Failure, Cytokine Storm, COVID 19, SARS-CoV-2, Cardiac Event, Cardiac Complication, Cardiac Failure, Cardiac Infarct
Interventions
Pemziviptadil (PB1046), Low Dose (10 mg) Control
Drug
Lead sponsor
PhaseBio Pharmaceuticals Inc.
Industry
Eligibility
18 Years to 85 Years
Enrollment
54 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2020
U.S. locations
4
States / cities
Jacksonville, Florida • Sarasota, Florida • Kansas City, Kansas + 1 more
Source: ClinicalTrials.gov public record
Updated Dec 10, 2020 · Synced Sep 10, 2026, 4:40 PM EDT
Completed No phase listed Observational

Use of Oxygen Hoods in Patients Failing on Conventional High-flow Oxygen Delivery Systems, Effects on Oxygenation in Hypoxic COVID-19 Patients. Prospective Cohort Study.

NCT04407260
View directory record Official record
Conditions
COVID -19, Respiratory Failure, Hypoxia
Interventions
Oxygen Hood
Device
Lead sponsor
Northwell Health
Other
Eligibility
Not listed
Enrollment
136 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2020
U.S. locations
1
States / cities
Sleepy Hollow, New York
Source: ClinicalTrials.gov public record
Updated Dec 1, 2022 · Synced Sep 10, 2026, 4:40 PM EDT
Completed Not applicable Interventional Accepts healthy volunteers

GlowTest COVID-19 Antigen Home Test Kit QRI Use Study

NCT05140005
View directory record Official record
Conditions
Covid 19
Interventions
GlowTest COVID-19 Antigen Home Test
Diagnostic Test
Lead sponsor
Arion Bio
Industry
Eligibility
2 Years and older
Enrollment
33 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2021
U.S. locations
1
States / cities
Elkridge, Maryland
Source: ClinicalTrials.gov public record
Updated Dec 19, 2021 · Synced Sep 10, 2026, 4:40 PM EDT
Completed Phase 2 Interventional Results available

A Double-blind, Placebo-controlled Clinical Trial of Fluvoxamine for Symptomatic Individuals With COVID-19 Infection

NCT04342663
View directory record Official record
Conditions
COVID 19, Coronavirus
Interventions
Fluvoxamine, Placebo
Drug
Lead sponsor
Washington University School of Medicine
Other
Eligibility
18 Years and older
Enrollment
152 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2020
U.S. locations
2
States / cities
Belleville, Illinois • St Louis, Missouri
Source: ClinicalTrials.gov public record
Updated Jul 8, 2021 · Synced Sep 10, 2026, 4:40 PM EDT
Completed Phase 3 Interventional Results available

LY3819253 (LY-CoV555) for Inpatients With COVID-19 (An ACTIV-3/TICO Treatment Trial)

NCT05780268
View directory record Official record
Conditions
COVID-19
Interventions
LY3819253, Placebo, Remdesivir
Biological
Lead sponsor
National Institute of Allergy and Infectious Diseases (NIAID)
NIH
Eligibility
18 Years and older
Enrollment
314 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2020 – 2021
U.S. locations
42
States / cities
Tucson, Arizona • Fresno, California • Los Angeles, California + 32 more
Source: ClinicalTrials.gov public record
Updated Dec 26, 2023 · Synced Sep 10, 2026, 4:40 PM EDT
Recruiting Not applicable Interventional Accepts healthy volunteers

Neural Mechanisms of Fatigue in Post-Acute Sequela of SARS-CoV-2

NCT07278388
View directory record Official record
Conditions
PASC Post Acute Sequelae of COVID 19, Fatigue
Interventions
Physical Fatigue
Behavioral
Lead sponsor
Hugo W. Moser Research Institute at Kennedy Krieger, Inc.
Other
Eligibility
18 Years to 75 Years
Enrollment
200 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2025 – 2029
U.S. locations
1
States / cities
Baltimore, Maryland
Source: ClinicalTrials.gov public record
Updated Dec 11, 2025 · Synced Sep 10, 2026, 4:40 PM EDT
No Longer Available No phase listed Expanded access

Evaluating the Use of Polymyxin B Cartridge Hemoperfusion for Patients With Septic Shock and COVID 19

NCT04352985
View directory record Official record
Conditions
Septic Shock, Endotoxemia, COVID, Corona Virus Infection, Sepsis, Severe
Interventions
Toraymyxin PMX-20R (PMX Cartridge)
Device
Lead sponsor
Spectral Diagnostics (US) Inc.
Industry
Eligibility
18 Years and older
U.S. locations
3
States / cities
Farmington, Connecticut • Washington D.C., District of Columbia • Stony Brook, New York
Source: ClinicalTrials.gov public record
Updated Sep 19, 2021 · Synced Sep 10, 2026, 4:40 PM EDT
Recruiting No phase listed Observational Accepts healthy volunteers

Preparedness Through Respiratory Virus Epidemiology and Community Engagement

NCT07147517
View directory record Official record
Conditions
Respiratory Infection Virus, COVID -19, RSV, FLU
Interventions
Component A0, Component A1, Component A2, Component B
Other
Lead sponsor
University of California, San Diego
Other
Eligibility
Not listed
Enrollment
25,000 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2025 – 2030
U.S. locations
2
States / cities
La Jolla, California • San Ysidro, California
Source: ClinicalTrials.gov public record
Updated Nov 3, 2025 · Synced Sep 10, 2026, 4:40 PM EDT
Completed Not applicable Interventional

Awake Prone Position in Hypoxemic Patients With Coronavirus Disease 19 COVID-19 (COVI-PRONE)

NCT04350723
View directory record Official record
Conditions
Corona Virus Infection, Covid19, COVID-19
Interventions
Awake Proning
Procedure
Lead sponsor
St. Joseph's Healthcare Hamilton
Other
Eligibility
18 Years and older
Enrollment
400 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2020 – 2021
U.S. locations
1
States / cities
Dallas, Texas
Source: ClinicalTrials.gov public record
Updated Oct 14, 2021 · Synced Sep 10, 2026, 4:40 PM EDT
Completed No phase listed Observational Accepts healthy volunteers

COVID-19 Knowledge, Attitudes, Practices and Perceived Risk: Cross Sectional Mixed Methods

NCT07021716
View directory record Official record
Conditions
COVID - 19, Multiple Sclerosis
Interventions
No Interventions
Other
Lead sponsor
Hunter College of City University of New York
Other
Eligibility
18 Years and older
Enrollment
148 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2020
U.S. locations
1
States / cities
New York, New York
Source: ClinicalTrials.gov public record
Updated Jun 14, 2025 · Synced Sep 10, 2026, 4:40 PM EDT
Completed Phase 3 Interventional

ACTIV-3: Therapeutics for Inpatients With COVID-19

NCT04501978
View directory record Official record
Conditions
Covid19
Interventions
LY3819253, Placebo, Remdesivir, VIR-7831, BRII-196/BRII-198, AZD7442, MP0420, PF-07304814
Biological · Drug
Lead sponsor
National Institute of Allergy and Infectious Diseases (NIAID)
NIH
Eligibility
18 Years and older
Enrollment
2,753 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2020 – 2023
U.S. locations
98
States / cities
Tucson, Arizona • Chula Vista, California • Fresno, California + 64 more
Source: ClinicalTrials.gov public record
Updated Aug 24, 2023 · Synced Sep 10, 2026, 4:40 PM EDT
Terminated Phase 2 Interventional Results available

Tocilizumab for Patients With Cancer and COVID-19 Disease

NCT04370834
View directory record Official record
Conditions
Hematopoietic and Lymphoid Cell Neoplasm, Malignant Solid Neoplasm, Pneumonia, Pneumonitis, Severe Acute Respiratory Distress Syndrome, Symptomatic COVID-19 Infection Laboratory-Confirmed
Interventions
Tocilizumab
Biological
Lead sponsor
National Cancer Institute (NCI)
NIH
Eligibility
2 Years and older
Enrollment
1 participant
Healthy volunteers
Healthy volunteers not accepted
Timeline
2020 – 2021
U.S. locations
5
States / cities
Rockville, Maryland • Las Vegas, Nevada • Oklahoma City, Oklahoma + 1 more
Source: ClinicalTrials.gov public record
Updated Feb 3, 2025 · Synced Sep 10, 2026, 4:40 PM EDT
Terminated Phase 2Phase 3 Interventional Results available

Trial of Hydroxychloroquine In Covid-19 Kinetics

NCT04353271
View directory record Official record
Conditions
Covid 19, Corona Virus Infection
Interventions
Hydroxychloroquine, Placebo
Drug · Other
Lead sponsor
University of South Alabama
Other
Eligibility
19 Years to 85 Years
Enrollment
3 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2020
U.S. locations
1
States / cities
Mobile, Alabama
Source: ClinicalTrials.gov public record
Updated Jan 2, 2022 · Synced Sep 10, 2026, 4:40 PM EDT
Completed No phase listed Observational

Covid-19 Vaccine Responsiveness in MM and Waldenstrom

NCT04830046
View directory record Official record
Conditions
Multiple Myeloma, Waldenstrom Macroglobulinemia, Immune System Disorder, Covid19
Interventions
Not listed
Lead sponsor
Massachusetts General Hospital
Other
Eligibility
18 Years and older
Enrollment
146 participants
Timeline
2021 – 2022
U.S. locations
2
States / cities
Boston, Massachusetts
Source: ClinicalTrials.gov public record
Updated Nov 25, 2025 · Synced Sep 10, 2026, 4:40 PM EDT
Completed Phase 2 Interventional Results available

Double-blind Study to Evaluate the Safety and Efficacy of Antroquinonol in Mild-Moderate COVID-19 Hospitalized Patients

NCT04523181
View directory record Official record
Conditions
Covid-19
Interventions
Antroquinonol, Placebo
Drug · Other
Lead sponsor
Golden Biotechnology Corporation
Industry
Eligibility
18 Years to 80 Years
Enrollment
124 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2020 – 2021
U.S. locations
5
States / cities
Michigan City, Indiana • Wichita, Kansas • Rockville, Maryland + 2 more
Source: ClinicalTrials.gov public record
Updated Dec 12, 2023 · Synced Sep 10, 2026, 4:40 PM EDT
Completed No phase listed Observational Accepts healthy volunteers

Advance Care Planning: Communicating With Outpatients for Vital Informed Decision

NCT04660422
View directory record Official record
Conditions
Advanced Care Planning, Shared Decision Making, Video Decision Aids, Communication Skills, Advance Directives, Natural Language Processing, Covid19
Interventions
VitalTalk communication skills training, ACP Decisions Video Program, Intervention training:, Medical Record Review
Other
Lead sponsor
Dana-Farber Cancer Institute
Other
Eligibility
65 Years and older
Enrollment
42,019 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2020 – 2021
U.S. locations
1
States / cities
New Hyde Park, New York
Source: ClinicalTrials.gov public record
Updated Jul 4, 2022 · Synced Sep 10, 2026, 4:40 PM EDT
Completed Phase 2 Interventional Results available

To Evaluate the Safety and Efficacy of TQ Formula in Covid-19 Participants

NCT04914377
View directory record Official record
Conditions
Covid19
Interventions
TQ Formula/Tab
Drug
Lead sponsor
Novatek Pharmaceuticals
Industry
Eligibility
18 Years and older
Enrollment
55 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2021 – 2022
U.S. locations
3
States / cities
San Diego, California • Hialeah, Florida • Houston, Texas
Source: ClinicalTrials.gov public record
Updated Aug 13, 2024 · Synced Sep 10, 2026, 4:40 PM EDT
Active, not recruiting Phase 2Phase 3 Interventional

SARS-Cov-2 (COVID-19) Nasal Pharyngeal and Oral Pharyngeal Wash (SNOW) Trial

NCT04802408
View directory record Official record
Conditions
Covid19, SARS-CoV Infection
Interventions
Shampoo and saline, Saline and Listerine, Shampoo and Listerine, Saline and Saline
Combination Product
Lead sponsor
Milton S. Hershey Medical Center
Other
Eligibility
18 Years to 65 Years
Enrollment
171 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2021 – 2026
U.S. locations
2
States / cities
Hershey, Pennsylvania • State College, Pennsylvania
Source: ClinicalTrials.gov public record
Updated Oct 27, 2025 · Synced Sep 10, 2026, 4:40 PM EDT
Not listed Phase 4 Interventional

An Outpatient Clinical Trial Using Ivermectin and Doxycycline in COVID-19 Positive Patients at High Risk to Prevent COVID-19 Related Hospitalization

NCT04729140
View directory record Official record
Conditions
Covid19
Interventions
Ivermectin Tablets, Doxycycline Tablets, Placebo
Drug
Lead sponsor
Max Health, Subsero Health
Other
Eligibility
18 Years and older
Enrollment
150 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2020 – 2022
U.S. locations
1
States / cities
Sarasota, Florida
Source: ClinicalTrials.gov public record
Updated Mar 31, 2021 · Synced Sep 10, 2026, 4:40 PM EDT
Completed No phase listed Observational

Neurologic Manifestations of COVID 19 in Children

NCT04379089
View directory record Official record
Conditions
COVID, Neurologic Manifestations
Interventions
Observational study only
Other
Lead sponsor
University of Pittsburgh
Other
Eligibility
Up to 17 Years
Enrollment
3,568 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2020 – 2022
U.S. locations
1
States / cities
Pittsburgh, Pennsylvania
Source: ClinicalTrials.gov public record
Updated Jan 26, 2023 · Synced Sep 10, 2026, 4:40 PM EDT
Completed Phase 2 Interventional Results available

A Study to Evaluate the Efficacy and Safety of Sirukumab in Confirmed Severe or Critical Confirmed Coronavirus Disease (COVID)-19

NCT04380961
View directory record Official record
Conditions
Critical Confirmed Coronavirus Disease (COVID)-19
Interventions
Sirukumab, Placebo, Standard of Care (SOC)
Drug · Other
Lead sponsor
Janssen Pharmaceutica N.V., Belgium
Industry
Eligibility
18 Years to 84 Years
Enrollment
212 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2020 – 2021
U.S. locations
16
States / cities
Long Beach, California • Newport Beach, California • Fort Lauderdale, Florida + 13 more
Source: ClinicalTrials.gov public record
Updated Jun 20, 2022 · Synced Sep 10, 2026, 4:40 PM EDT
Completed Phase 2 Interventional Results available

Treatment With CSL312 in Adults With Coronavirus Disease 2019 (COVID-19)

NCT04409509
View directory record Official record
Conditions
Coronavirus Disease 2019 (COVID-19)
Interventions
Garadacimab, Factor XIIa Antagonist Monoclonal Antibody, Placebo
Biological · Drug
Lead sponsor
CSL Behring
Industry
Eligibility
18 Years and older
Enrollment
124 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2020 – 2021
U.S. locations
14
States / cities
Bradenton, Florida • St. Petersburg, Florida • Mason City, Iowa + 11 more
Source: ClinicalTrials.gov public record
Updated Jan 23, 2022 · Synced Sep 10, 2026, 4:40 PM EDT